EyePoint Pharmaceuticals (EYPT) Tops Q3 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts EYPT Hot Sheet
Join SI Premium – FREE
EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q3 EPS of ($0.33), $0.17 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $15.2 million versus the consensus estimate of $7.86 million.
For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho Downgrades EyePoint Inc. (EYPT) to Neutral 'on Negative P3 Data, Lack of Catalysts, Financing Overhang'
- Knowles (KN) Tops Q3 EPS by 2c; offers guidance
- Farmers & Merchants Bancorp, Inc. (FMAO) Tops Q3 EPS by 4c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
